Organization (Industry)
Westat (United States)
ClinicalTrials.gov lists Westat (United States) as lead sponsor of 23 trials. It has 8 active development programs and 8 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 5 registered with a 2026 start date. The dashed outline is the pace from the 5 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
This page covers Westat (United States): 23 lead-sponsored trials and 1 legal-entity registration.
Disease areas (60)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| HIV Infections | 6 |
| Diabetes Mellitus | 5 |
| Acquired Immunodeficiency Syndrome | 3 |
| Hypertension | 3 |
| Obesity | 3 |
Showing 5 of 60 disease areas.
Trials by start year as sponsor or collaborator (16)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 6 |
| 2024 | 2 |
| 2023 | 3 |
| 2022 | 6 |
| 2021 | 2 |
| 2019 | 5 |
| 2018 | 1 |
| 2017 | 5 |
| 2016 | 4 |
Showing 10 of 16 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (8)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Lithium | Corticobasal Degeneration | Phase 1/2 | 1 |
| Lithium | Dementia | Phase 1/2 | 1 |
| Lithium | Supranuclear Palsy, Progressive | Phase 1/2 | 1 |
| Lithium | Pick Disease of the Brain | Phase 1/2 | 1 |
| Lithium | Frontotemporal Dementia | Phase 1/2 | 1 |
Showing 5 of 8 active programs.
Approved assets (8)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Lamivudine-Zidovudine (3TC-ZDV) | 1 |
| Doxycycline hyclate delayed released 200 mg weekly | 1 |
| Raltegravir | 1 |
| Efavirenz | 1 |
| Doxycycline hyclate delayed released 200 mg | 1 |
Showing 5 of 8 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 22% hit target (n=9) | 43% on time (n=7) |
Journals published in (85)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Administration and policy in mental health | 11 |
| BMC health services research | 5 |
| BMC psychiatry | 5 |
| Journal of nutrition education and behavior | 5 |
| Preventing chronic disease | 4 |
Showing 5 of 85 journals.
Financing and grant events (125)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-30 | NIH grant | 1,737,858 | Reporter |
| 2025-09-30 | NIH grant | 462,520 | Reporter |
| 2025-09-30 | NIH grant | 7,570,746 | Reporter |
| 2025-09-30 | NIH grant | 535,000 | Reporter |
| 2025-09-30 | NIH grant | 193,451 | Reporter |
Showing 5 of 125 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 2 |
Organization relationships (23)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 17 |
| The Emmes Company, LLC | Uses vendor | 2 |
| University of California System | Co sponsors trial with | 2 |
| Wayne State University | Co sponsors trial with | 1 |
| Medical University of South Carolina | Co sponsors trial with | 1 |
Showing 5 of 23 relationships.
Latest dated events (182)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 182 events.
Biomarker capability evidence (97)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial collaborator | Named in trial inclusion criteria |
| F2 | Trial collaborator | Named in trial inclusion criteria |
| F2 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 97 evidence rows.
On Scientist.com
Westat (United States) is listed as a research supplier in the Scientist.com network.
Service areas
Westat offers clinical research services including data management, study design, project management, site management, and biostatistical design in the therapeutic areas of infectious disease and oncology.
- Website
- www.westat.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Westat on Scientist.com
For prices, more details, or to contact Westat, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.